American Express
AXP
$324.31
+1.03%
American Express is a global financial institution operating in roughly 130 countries, providing consumers and businesses with charge and credit card payment products alongside a highly profitable closed-loop merchant payment network, organized across US consumer services, US commercial services, international card services, and global merchant and network services. Its distinctive competitive identity rests on a premium, high-spending cardholder base, a proprietary network that captures both merchant discount revenue and card economics, and a brand that functions as a lifestyle and status asset rather than a commodity payment rail — a structure that has historically supported superior credit quality and pricing power versus bank-issued card peers. The current investor narrative centers on the company's record third-quarter 2026 results, with 9% revenue growth, raised full-year guidance, and management's emphasis on AI integration and premium customer engagement to sustain growth, themes amplified by the stock's status as one of Berkshire Hathaway's largest and longest-held positions. Against that constructive fundamental backdrop, the debate has shifted to valuation and relative performance: shares have lagged a rising market over the past year even as earnings estimates climb, leaving investors to weigh whether the premium franchise is temporarily de-rated or whether consumer credit normalization and a high-teens forward multiple cap the upside.…
AXP
American Express
$324.31
Related headlines
Investment Opinion: Should I buy AXP Today?
Rating: Buy (moderate conviction). The thesis is that AXP offers a premium closed-loop franchise with expanding margins and a 32.36% ROE at only 15.88x forward earnings, while the Street's $365.79 average target implies +14.0% upside and even the lowest target of $329.00 sits above the current $320.99. The analyst consensus of "buy" (recommendation mean 2.21, 14 Buys, 15 Holds, zero Sells) anchors a view that the year-long de-rating has gone far enough to compensate for credit-normalization risk.
Supporting evidence is concrete: Q3 2026 net income rose 27.9% YoY to $3.712 billion with net margin at 16.89% versus 14.40% in Q2 and 14.23% in Q1, while gross margin climbed sequentially from 84.56% to 85.91% to 86.79%. Revenue re-accelerated through the year ($20.88B to $21.60B to $21.98B) and grew 6.92% YoY, and TTM free cash flow of $13.911 billion (about a 5.4% FCF yield on the $257.1 billion market cap) funds the $668 million quarterly dividend at a 20.96% payout ratio plus $1.59 billion of Q3 buybacks. The valuation spread is the key support: 15.88x forward versus 24.01x trailing is a 34% compression, and the implied 12.7x multiple on consensus 2027 EPS of $28.70 is undemanding for a franchise earning 32.36% on equity.
The biggest risks that could invalidate the thesis are consumer credit normalization hitting the 16.89% net margin, a funding-cost squeeze on the 1.73x debt-to-equity balance sheet (Q3 interest expense of $1.918 billion), and multiple compression from the 7.68x price-to-book, which sits above the 5.7x-7.6x band of the past year. The rating would upgrade to a higher-conviction Buy if Q4 confirms margin expansion and revenue holds near 7% growth with the stock reclaiming the $361.57 July high, and it would downgrade to Hold if revenue growth decelerates toward low single digits or the price breaks the $290.97 52-week low. Net verdict: the stock looks modestly undervalued relative to its own history on forward earnings, but fairly valued to slightly rich on book and PEG (2.46), so the margin of safety is moderate rather than deep.
Sign up to view all
AXP 12-Month Price Forecast
The forward-looking case is constructive but not high-conviction: earnings are inflecting with margins expanding for three consecutive quarters, and a 15.88x forward multiple for a 32.36% ROE franchise prices in considerable credit caution rather than franchise deterioration. The Street's complete absence of Sell ratings and a low target above the current price provide a valuation floor of sorts, while the $365.79 average target and 12.7x implied multiple on 2027 EPS frame a realistic base-case return of roughly +14%. The offsetting evidence is the -21.82% one-year relative underperformance, a 7.68x price-to-book above its own recent band, and a PEG of 2.46 that leaves little room for a credit surprise. I would upgrade to high confidence if Q4 confirms net margin above 16% and the stock breaks the $361.57 July high, and I would downgrade to neutral if revenue growth slips toward low single digits or the price loses the $290.97 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on American Express's 12-month outlook, with a consensus price target around $364.79 and implied upside of +12.5% versus the current price.
Average Target
$364.79
29 analysts
Implied Upside
+12.5%
vs. current price
Analyst Count
29
covering this stock
Price Range
$329 - $425
Analyst target range
Coverage is broad and moderately constructive: 24 analysts, with 14 Buy ratings, 15 Hold ratings, and zero Sells, yielding a recommendation mean of 2.21 (a Buy on the firm's scale) and a consensus recommendation of "buy." The average target price of $365.79 implies roughly +14.0% upside from the current $320.99, and notably the lowest target of $329.00 sits above the current price — meaning even the most cautious analyst sees modest appreciation. The consensus leans cautiously bullish: the absence of any Sell ratings is a strong signal, but the 15 Hold ratings against 14 Buys indicates the Street sees fair value being approached rather than a deep discount.
The target range of $329.00 to $425.00 is wide — a 29% spread from low to high — signaling genuine disagreement about the durability of the growth trajectory. The $425 high target implies multiple expansion toward 18-20x forward earnings and confidence that premium spending, AI-driven engagement, and international growth sustain high-single-digit revenue gains; the $329 low target essentially prices in flat-to-modest multiple re-rating with credit normalization offsetting earnings growth. Recent institutional actions show stability rather than momentum: UBS, Citigroup, Barclays, Morgan Stanley, and TD Cowen have reiterated Neutral/Equal Weight/Hold stances through October and November 2026, while JP Morgan and RBC Capital maintain Overweight/Outperform — a pattern of conviction without fresh upgrades. With consensus 2027 EPS of $28.70 and revenue of $76.42 billion, the average target implies roughly 12.7x forward earnings, suggesting analysts see the current de-rating as an opportunity rather than a warning.
Bulls vs Bears: AXP Investment Factors
The bull case currently has the stronger evidence: earnings are inflecting (Q3 net income +27.9% YoY, net margin up 249bps sequentially), the forward multiple of 15.88x is undemanding for a 32.36% ROE franchise, no analyst carries a Sell, and one-month relative strength has swung +10.49% versus SPY. The bear case rests less on fundamentals than on price action and positioning — a -21.82% one-year relative underperformance, a 7.68x P/B above its own recent band, and a Street split 15 Hold to 14 Buy that says fair value is being approached. The single most important tension is whether the 34% trailing-to-forward PE compression is the market correctly pricing consumer credit normalization, or an overreaction to a franchise whose margins are actually expanding. If Q4 confirms margin expansion and revenue holds near 7% growth, the de-rating resolves upward toward the $365.79 consensus target; if credit costs normalize faster than spending grows, the 15.88x forward multiple proves to be a value trap rather than a discount.
Bullish
- Earnings inflecting sharply, margins expanding: Q3 2026 net income rose 27.9% YoY to $3.712 billion from $2.902 billion, with net margin expanding to 16.89% from 14.40% in Q2 and 14.23% in Q1. Gross margin climbed sequentially from 84.56% to 85.91% to 86.79% across the first three quarters, showing operating leverage rather than a one-off beat.
- Forward multiple undemanding for 32% ROE: The stock trades at 15.88x forward earnings against a 24.01x trailing PE, a 34% compression implying the market expects meaningful EPS growth (consensus 2027 EPS of $28.70). A 32.36% ROE and 86.79% gross margin are structurally superior to balance-sheet-only bank card issuers, making ~16x forward look cheap relative to franchise quality.
- No Sell ratings, average target +14%: All 24 covering analysts rate Buy (14) or Hold (15) with zero Sells, and the $365.79 average target implies +14.0% upside from $320.99. Critically, even the lowest target of $329.00 sits above the current price, meaning the most cautious analyst still sees appreciation.
- Momentum reversing versus the market: The stock has gained 5.50% over the past month versus a -4.99% decline in SPY, a +10.49% relative-strength swing that sharply reverses the -21.82% one-year underperformance. The six-month change of +1.57% versus SPY -0.54% confirms the intermediate trend has stabilized into a base-building pattern of higher lows since the September trough.
Bearish
- Severe relative underperformance persists: The stock is down 12.23% over the trailing year and 13.88% YTD versus the S&P 500's +9.59% and +7.83%, producing -21.82% twelve-month relative strength. A 24.06% maximum drawdown shows the de-rating was deep, and the failure to hold above $330 on the November 4 push to $332.59 argues the recovery is not yet confirmed.
- Valuation premium on book and PEG: Price-to-book of 7.68x sits above the 5.7x-7.6x range seen over the past year, and the PEG ratio of 2.46 signals investors are paying up relative to growth. The 3.20x price-to-sales and 17.16x EV/EBITDA place AXP at a premium to traditional bank card issuers, leaving little room for credit deterioration.
- Street split signals fair value approached: The 15 Hold ratings against 14 Buys, with a recommendation mean of 2.21, indicate the consensus sees fair value being approached rather than a deep discount. Recent institutional actions from UBS, Citigroup, Barclays, Morgan Stanley, and TD Cowen were all reiterations of Neutral/Equal Weight/Hold through October and November 2026 — conviction without fresh upgrades.
- Leverage and liability-heavy balance sheet: Debt-to-equity of 1.73x and total-debt-to-capitalization of 62.6% are normal for a card issuer but leave the model sensitive to funding costs, with $1.918 billion of Q3 interest expense. The current ratio of 0.284 reflects a bank-like structure where a consumer credit downturn would hit the receivables book directly.
AXP Technical Analysis
American Express is in a medium-term recovery within a longer-term corrective phase. The stock is down 12.23% over the trailing year and 13.88% year-to-date, a stark contrast to the S&P 500's +9.59% one-year and +7.83% YTD gains, producing relative strength of -21.82% over twelve months. At the current price of $320.99, the stock sits roughly 30.0 points above its 52-week low of $290.97 and about 66.5 points below its 52-week high of $387.49 — approximately 44% of the way through that range, positioning it in neutral-to-lower territory rather than at momentum extremes. The 24.06% maximum drawdown confirms the correction was deep enough to reset sentiment, but the price is no longer near the lows, suggesting the selling pressure has largely been absorbed rather than signaling a falling knife.
Short-term momentum has turned decisively positive and is diverging from the weak annual trend. The stock has gained 5.50% over the past month versus a -4.99% decline in SPY, generating relative strength of +10.49% — a sharp reversal from the -21.82% one-year relative underperformance. The three-month change of -5.84% (versus SPY -4.91%) shows the recovery is recent, with the June-to-July rally to $361.57 followed by a pullback to the $301-$306 area in late September and a subsequent rebound to $332.59 on November 4 before the latest -1.22% session to $320.99. The six-month change of +1.57% versus SPY -0.54% (+2.11% relative strength) confirms the intermediate trend has stabilized; the pattern of higher lows since the September trough is characteristic of a base-building phase rather than a renewed downtrend, though the failure to hold above $330 on the most recent push argues for patience.
Key technical levels are well defined. Support clusters at the 52-week low of $290.97, with secondary support in the $301-$306 zone that held in late September and early October; resistance sits at the 52-week high of $387.49, with an intermediate ceiling near the July high of $361.57 and the recent $332.59 swing high. A breakout above $361.57 would signal the corrective phase is over and likely open a retest of the highs, while a breakdown below $290.97 would invalidate the recovery and expose the stock to further downside. With a beta of 1.077, the stock carries roughly 8% more volatility than the market — modest for a financial, but still requiring position sizing that accounts for the 24% peak-to-trough drawdown already experienced this year; the short ratio of 3.13 days suggests no meaningful short-squeeze fuel either way.
Beta
1.08
1.08x market volatility
Max Drawdown
-24.1%
Largest decline past year
52-Week Range
$291-$387
Price range past year
Annual Return
-12.0%
Cumulative gain past year
| Period | AXP Return | S&P 500 |
|---|---|---|
| 1m | +5.2% | -3.3% |
| 3m | -4.8% | -2.3% |
| 6m | +4.7% | +1.4% |
| 1y | -12.0% | +12.2% |
| ytd | -13.0% | +10.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXP Fundamental Analysis
Revenue is growing steadily and, importantly, re-accelerating on a sequential basis. Third-quarter 2026 revenue reached $21.98 billion, up 6.92% year-over-year from $20.557 billion, and up from $21.595 billion in Q2 and $20.88 billion in Q1 — a clear sequential build through the year. The year-over-year comparison also improved versus Q2's growth off a $19.933 billion base, and the segment mix shows Global Consumer Services Group contributing $9.84 billion, Global Commercial Services $4.553 billion, International Card Services $3.682 billion, and Global Merchant and Network Services $2.082 billion, with the consumer franchise the largest growth engine. Consensus revenue estimates of $76.42 billion (range $75.37-$77.05 billion) imply continued mid-single-digit expansion, consistent with a premium-spend model that compounds with cardholder spending rather than requiring balance-sheet leverage.
Profitability is robust and margins are expanding. Q3 2026 net income was $3.712 billion on a net margin of 16.89%, up from $3.11 billion and 14.40% in Q2 and $2.971 billion and 14.23% in Q1; year-over-year, net income rose from $2.902 billion in Q3 2025, a 27.9% increase. Gross margin of 86.79% in Q3 versus 85.91% in Q2 and 84.56% in Q1 shows consistent expansion, while the trailing operating margin of 17.14% and net margin of 13.46% reflect the full-year blend including the seasonally weaker Q4. Diluted EPS of $5.43 in Q3 compares with $4.54 in Q2 and $4.14 in the year-ago quarter, and the 32.36% ROE is exceptional for a financial — well above the high-teens returns typical of large bank card issuers — reflecting the capital-light network economics layered atop the lending book.
Balance sheet and cash generation are healthy but require context for a lender. Debt-to-equity of 1.73x and a total-debt-to-capitalization ratio of 62.6% are normal for a card issuer funding a receivables book, and the current ratio of 0.284 reflects the liability-heavy structure of a bank-like balance sheet rather than distress. Free cash flow of $13.911 billion TTM and $4.437 billion in Q3 alone comfortably fund the $668 million quarterly dividend (payout ratio 20.96%, yield 0.88%) and $1.59 billion of Q3 buybacks, with $43.2 billion of cash at period end. The FCF yield of roughly 5.4% on the $257.1 billion market cap, combined with a 0.83 FCF/operating-cash-flow conversion ratio, indicates the company self-funds growth and shareholder returns without external financing dependence.
Quarterly Revenue
$22.0B
2026-09
Revenue YoY Growth
+6.9%
YoY Comparison
Gross Margin
86.8%
Latest Quarter
Free Cash Flow
$13.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXP Overvalued?
Because net income is solidly positive ($3.712 billion in Q3, $13.9 billion TTM free cash flow), the PE ratio is the appropriate primary metric. The stock trades at 24.01x trailing earnings but only 15.88x forward earnings — a 34% compression that implies the market expects meaningful EPS growth, consistent with consensus 2027 EPS of $28.70 versus the current run-rate. The PEG ratio of 2.46 and price-to-book of 7.68x are the more demanding data points: the forward multiple is reasonable for a franchise with 32% ROE, but the trailing premium reflects a year of multiple compression rather than expansion.
Peer comparison is constrained by the absence of a supplied industry-average multiple, but the internal spread is informative: a 15.88x forward PE against a 24.01x trailing PE and a 3.20x price-to-sales ratio places AXP at a premium to traditional bank card issuers on book value (7.68x P/B) but at a discount to high-growth payment networks on forward earnings. The 17.16x EV/EBITDA and 3.18x EV/Sales sit between those poles, consistent with a hybrid lender-network model. The premium to book is justified by the 32.36% ROE and 86.79% gross margin, which are structurally superior to balance-sheet-only lenders; the discount to pure networks reflects credit risk embedded in the lending book.
Historical context shows the stock is near the cheaper end of its own recent band. The trailing PE of 24.01x compares with 26.20x at year-end 2025, 20.06x in Q3 2025, and 14.00x in the most recent quarterly ratio snapshot, while the price-to-sales ratio of 3.20x is far below the 9.3x-12.1x readings recorded across 2025-2026 quarterly snapshots (a discrepancy likely reflecting differing share-count or revenue bases). The price-to-book of 7.68x is above the 5.7x-7.6x range seen over the past year, suggesting book value has grown into the multiple. Net-net, the forward earnings multiple near 16x for a 32%-ROE franchise with 7% revenue growth looks undemanding relative to its own history, implying the market is pricing caution on credit and consumer spending rather than franchise deterioration.
PE
24.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 11x~25x
vs. Industry Avg
14.2x
Industry PE ~14.2x*
EV/EBITDA
17.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the lending book embedded in a premium franchise. Debt-to-equity of 1.73x and a 62.6% total-debt-to-capitalization ratio fund a receivables book that generated $1.918 billion of Q3 interest expense, so any rise in funding costs or cardmember delinquency flows directly to the 16.89% net margin. The current ratio of 0.284 is structural for a bank-like balance sheet, not distress, but it means liquidity depends on continued access to wholesale funding. Earnings quality is also seasonal and uneven — Q4 2025 net income of $2.462 billion on a 11.70% net margin was far below Q3 2026's $3.712 billion at 16.89% — so the trailing 13.46% net margin and 24.01x trailing PE embed a full-year blend that a weak holiday quarter could disappoint against. Revenue concentration in the US consumer franchise ($9.84 billion of Q3's $21.98 billion) ties results to premium cardholder spending, which is the most cyclical part of the model.
Market and competitive risks are dominated by valuation compression and sector rotation. At 7.68x book, above the 5.7x-7.6x band of the past year, and a PEG of 2.46, AXP carries a premium that assumes credit stays benign; a rotation out of financials or a consumer-spending scare would compress the multiple toward the 14.00x trailing PE snapshot seen in the most recent quarterly reading. The beta of 1.077 means roughly 8% more volatility than the market, so a broad risk-off move amplifies drawdowns, and the stock has already demonstrated a 24.06% peak-to-trough decline this year. Competitive pressure from BNPL players — Affirm's strong Q4 with rising card adoption was highlighted in recent coverage — and from bank-issued premium cards erodes the exclusivity that supports the closed-loop merchant discount rate. The absence of any Sell rating and the pattern of Neutral reiterations from UBS, Citigroup, Barclays, Morgan Stanley, and TD Cowen suggest the Street is not yet willing to underwrite multiple expansion, capping near-term re-rating potential.
The worst-case scenario is a consumer credit normalization that coincides with multiple compression. If unemployment rises and premium cardholders pull back spending, revenue growth decelerates from 6.92% toward low single digits while credit costs rise, hitting the 16.89% net margin and forcing analysts to cut the $28.70 2027 EPS estimate. In that chain, the stock would retest the 52-week low of $290.97 — about -9.4% from $320.99 — and a break below that level, which the technical picture flags as invalidating the recovery, would expose the 24.06% max drawdown as a template, implying a decline toward roughly $244 if the full drawdown repeated from the recent $332.59 swing high. The analyst low target of $329.00 offers little cushion, sitting only +2.5% above the current price, so the realistic adverse range is -9% to the 52-week low in a mild credit scare and -24% in a full drawdown repeat.
FAQ
Ranked by severity, credit and funding risk comes first: debt-to-equity of 1.73x and 62.6% total-debt-to-capitalization fund a receivables book that generated $1.918 billion of Q3 interest expense, so rising delinquency or funding costs flow straight into the 16.89% net margin. Second is earnings seasonality and volatility — Q4 2025 net income of $2.462 billion on an 11.70% net margin was far below Q3 2026's $3.712 billion at 16.89%, so a weak holiday quarter could disappoint against the 24.01x trailing PE. Third is valuation compression: at 7.68x book, above its own recent band, and a 2.46 PEG, the stock assumes benign credit, and a rotation out of financials with a beta of 1.077 would amplify drawdowns — the stock has already shown a 24.06% peak-to-trough decline this year. Fourth is competitive erosion, with BNPL players like Affirm posting strong Q4 results and rising card adoption alongside bank-issued premium cards, threatening the closed-loop exclusivity that supports merchant discount economics.
The 12-month outlook splits into three scenarios. The base case carries 50% probability with a $350.00-$365.79 range: earnings grow in line with consensus 2027 EPS of $28.70 and revenue of $76.42 billion, but the multiple stays anchored near 12.7x forward as credit normalization offsets margin gains, leaving the stock to grind toward the $365.79 average target. The bull case at 30% probability targets $387.49-$425.00, requiring Q4 to confirm net margin above 16% with revenue near 7% growth and a re-rating toward 18-20x forward earnings that carries the stock back through the $387.49 52-week high to the $425.00 analyst high. The bear case at 20% probability targets $290.97-$329.00, driven by credit normalization coinciding with multiple compression, estimate cuts to the $28.70 2027 EPS, and a retest of the 52-week low. The base case is most likely, and its key assumption is that net margin stays in the 14-17% band rather than repeating the 11.70% Q4 2025 trough.
The answer depends on the metric, and the spread is the story. On forward earnings the stock looks modestly undervalued: 15.88x forward versus 24.01x trailing is a 34% compression, and the $365.79 average target implies roughly 12.7x consensus 2027 EPS of $28.70 — undemanding for a business earning 32.36% on equity with an 86.79% gross margin. On book value it looks rich: 7.68x price-to-book sits above the 5.7x-7.6x range of the past year, and the 2.46 PEG and 3.20x price-to-sales signal investors are paying up relative to growth. Historical context supports the cheaper read — the trailing PE of 24.01x compares with 26.20x at year-end 2025 and 20.06x in Q3 2025, so the multiple has already de-rated. Net-net the market appears to be pricing caution on consumer credit and premium spending rather than franchise deterioration, which is why the verdict is modestly undervalued on forward earnings but fairly valued to slightly rich on book and PEG.
On a risk/reward basis the setup is moderately favorable: at $320.99 the stock sits 14.0% below the $365.79 analyst average target, and even the most cautious of the 24 covering analysts carries a $329.00 target above the current price, with zero Sell ratings across the Street. The fundamental case is that Q3 2026 net income rose 27.9% YoY to $3.712 billion with net margin expanding to 16.89% from 14.40% in Q2, while the stock trades at only 15.88x forward earnings for a 32.36% ROE franchise. The biggest downside risk is consumer credit normalization hitting that margin while the 7.68x price-to-book compresses toward its 5.7x-7.6x recent band, a path that could retest the $290.97 52-week low (-9.4%) or, in a full drawdown repeat, roughly $244 (-24%). It is a reasonable buy for patient investors with a 2-3 year horizon who size positions for a beta of 1.077 and a 24.06% max drawdown already experienced this year, but the 15 Hold versus 14 Buy split and 2.46 PEG argue for accumulating rather than chasing, and for waiting on Q4 confirmation of margin expansion before adding aggressively.
The profile favors long-term holding over short-term trading. AXP is a mature, capital-returning franchise — $13.911 billion of TTM free cash flow funds a $668 million quarterly dividend at a 20.96% payout ratio plus $1.59 billion of Q3 buybacks — with earnings visibility supported by 24 analysts, consensus 2027 EPS of $28.70, and a 6.92% revenue growth trajectory, all of which reward patience rather than tactical positioning. The 0.88% dividend yield is too small to anchor an income strategy, so the return case rests on multiple normalization toward the $365.79 average target and continued EPS growth. Short-term traders face a choppy tape: beta of 1.077, a 24.06% max drawdown this year, and a stock that pushed to $332.59 on November 4 before falling 1.22% to $320.99, with resistance at $361.57 and support at $290.97. A concrete minimum holding period of 2-3 years aligns with the credit cycle and the 2027 consensus earnings horizon, and investors should size positions for the roughly -9% to -24% adverse range identified in the bear case.